Aptose Biosciences Files Second Amendment to Going-Private Transaction Statement for Hanmi Acquisition

summarizeSummary

Aptose Biosciences filed an amendment to its Rule 13e-3 transaction statement, providing updated disclosures for its acquisition by Hanmi Pharmaceutical Co. Ltd. at C$2.41 per share, leading to delisting.

check_boxKey Events

• Updated Going-Private Disclosure

  Aptose Biosciences filed Amendment No. 2 to its SC 13E3, updating disclosures for the acquisition by Hanmi Pharmaceutical Co. Ltd. This follows the initial SC 13E3 filed on January 15, 2026, and a previous amendment on February 9, 2026.

• Acquisition Terms Confirmed

  The transaction involves HS North America Ltd. acquiring all outstanding common shares for C$2.41 (approximately USD $1.71) per share, a slight premium to the current stock price.

• Delisting Imminent

  Upon completion, Aptose will become a private entity, and its shares will be delisted from the Toronto Stock Exchange and OTC Markets.

• Board Recommendation

  The Board of Directors unanimously recommends shareholders approve the arrangement, supported by a fairness opinion from Locust Walk Securities, LLC.

auto_awesomeAnalysis

This filing, Amendment No. 2 to the SC 13E3, provides updated legal and financial disclosures in connection with the proposed acquisition of Aptose Biosciences by Hanmi Pharmaceutical Co. Ltd. It incorporates by reference the concurrently filed definitive proxy statement, signaling a critical step towards the completion of the going-private transaction. The acquisition, priced at C$2.41 (approximately USD $1.71) per common share, will result in Aptose becoming a wholly-owned subsidiary and its shares being delisted from public exchanges. The board, based on a fairness opinion, unanimously recommends shareholders approve the arrangement.